α-Hydroxy-α-methyl-1-naphthylessigsaeure | 6341-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: α-Hydroxy-α-methyl-1-naphthylessigsaeure
• 英文别名: 2-hydroxy-2-[1]naphthyl-propionic acid；2-Hydroxy-2-[1]naphthyl-propionsaeure；α-Oxy-α-(naphthyl-(1))-propionsaeure；Methyl-α-naphthyl-glykolsaeure；α-(Naphthyl-(1))-milchsaeure；2-Hydroxy-2-(naphthalen-1-yl)propanoic acid；2-hydroxy-2-naphthalen-1-ylpropanoic acid
• CAS: 6341-58-8
• 化学式: C₁₃H₁₂O₃
• mdl: MFCD14601983
• 分子量: 216.236
• InChiKey: GASZMNCYHARHHI-UHFFFAOYSA-N

物化性质

• 熔点：
  147-148 °C
• 沸点：
  431.4±25.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.153
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  α-Hydroxy-α-methyl-1-naphthylessigsaeure 、 N,N-二乙基氯乙胺 在 异丙醇 作用下， 生成 2-hydroxy-2-[1]naphthyl-propionic acid-(2-diethylamino-ethyl ester); hydrochloride
  参考文献：
  名称：

  Alkamine Esters of Substituted 1-Naphthaleneglycolic Acids¹

  摘要：

  DOI：

  10.1021/ja01227a006
• 作为产物：
  描述：

  2-hydroxy-2-[1]naphthyl-propionic acid isobutyl ester 在 氢氧化钾 作用下， 生成 α-Hydroxy-α-methyl-1-naphthylessigsaeure
  参考文献：
  名称：

  Lapkin; Golowkowa, Zhurnal Obshchei Khimii, 1948, vol. 18, p. 485,490

  摘要：

  DOI：

文献信息

• GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS
  申请人：South Dakota Board of Regents

  公开号：US20200048305A1

  公开（公告）日：2020-02-13

  The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms of such compositions. In addition, methods for treating subjects by administering such compositions are also disclosed.

  本发明描述了含有胆固醇-连接剂-谷胱甘肽共轭物的组合物，通过克服血脑屏障（BBB）进入中枢神经系统的屏障入口，包括这些组合物的胶束和脂质体形式。此外，还公开了通过给予这些组合物治疗受试者的方法。
• [EN] MACROMOLECULES FOR TREATING ATHEROSCLEROSIS<br/>[FR] MACROMOLÉCULES POUR LE TRAITEMENT DE L'ATHÉROSCLÉROSE
  申请人：UNIV RUTGERS

  公开号：WO2013188882A1

  公开（公告）日：2013-12-19

  The invention includes compounds of the formula I and formula II and salts thereof, as well as methods for using the compounds of formula I and formula II for treating atherosclerosis. The invention also includes compounds of formula III and (21) and salts thereof, as well as methods of using the compounds of formula III and (21) for treating atherosclerosis. The invention also includes methods of encapsulating molecules using the compounds of the invention.

  该发明包括公式I和公式II的化合物及其盐，以及使用公式I和公式II的化合物治疗动脉粥样硬化的方法。该发明还包括公式III和(21)的化合物及其盐，以及使用公式III和(21)的化合物治疗动脉粥样硬化的方法。该发明还包括使用该发明的化合物对分子进行封装的方法。
• AMPHIPHILIC MACROMOLECULES AND METHODS OF USE THEREOF
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US20160068467A1

  公开（公告）日：2016-03-10

  Certain embodiments of the invention provide a compound of formula (I): A-X—Y—Z—R 1 (I), or a salt thereof, wherein A, X, Y, Z and R 1 have any of the values defined in the specification, and methods of use thereof. For example, certain embodiments of the invention provide a method for inhibiting atherosclerosis or atherosclerotic development in a mammal, comprising administering to the mammal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

  本发明的某些实施例提供了化合物的结构式(I):A-X—Y—Z—R1(I)，或其盐，其中A、X、Y、Z和R1具有规范中定义的任何值，以及其使用方法。例如，本发明的某些实施例提供了一种方法，用于抑制哺乳动物中的动脉粥样硬化或动脉粥样硬化的发展，包括向哺乳动物施用化合物的有效量结构式(I)，或其药用盐。
• THERAPEUTIC HYPERBRANCHED POLYGLYCEROL ENCAPSULATED BIOMOLECULES
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160361425A1

  公开（公告）日：2016-12-15

  Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.

  本发明涉及改进口服、直肠或黏膜透传输的治疗生物分子（例如蛋白质）的方法，以及使用这些方法制备的组合物和将这些组合物用于治疗的方法。具体而言，本发明将治疗生物分子与高分支聚合物（HBPs）如高分支聚甘油（HPG）共轭。当这种共轭物被口服给予受试者时，HBP可以保护治疗生物分子免受胃酸环境和胃肠道的蛋白酶攻击，同时促进治疗生物分子在肠道更高的pH环境中的吸收。这些方法和组合物可用于改善给予受试者各种治疗生物分子的途径。
• POLYMERIC MICELLES FOR REDUCING LDL IN VIVO
  申请人：Uhrich Kathryn E.

  公开号：US20120219598A1

  公开（公告）日：2012-08-30

  The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also includes compounds of the formula I: A-X—Y—Z—R 1 (I) The invention includes methods of encapsulating molecules using the compounds of the invention.

  本发明涵盖了胶束组装体、含有胶束组装体的组合物以及制备胶束组装体和组合物的方法。本发明还包括公式I：A-X—Y—Z—R1(I)的化合物。本发明包括使用本发明化合物封装分子的方法。